Prophylaxis against herpesvirus infections in transplant recipients

Drugs

Volumn 61, Issue 2, 2001, Pages 187-196

  Ljungman, P ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; PENCICLOVIR; VALACICLOVIR;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG EFFICACY; EPSTEIN BARR VIRUS; GASTROINTESTINAL INFECTION; GRAFT INFECTION; HERPES SIMPLEX; HERPES VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION PREVENTION; KIDNEY TRANSPLANTATION; META ANALYSIS; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STEM CELL TRANSPLANTATION; VARICELLA ZOSTER VIRUS; VIRUS INFECTION;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; HERPES; HERPESVIRIDAE; HUMAN HERPESVIRUS 3; HUMAN HERPESVIRUS 4; SIMPLEXVIRUS;

EID: 0035090736     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161020-00004     Document Type: Review

References (63)

1. Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: Randomised double blind trial
2. Acyclovir prophylaxis of herpes-simplex-virus infections
3. Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro
4. Prevention of herpes simplex virus (HSV) infection in recipients of HLA-matched T-lymphocyte-depleted bone marrow allografts
5. Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir
6. Oral acyclovir for prevention of herpes simplex vires reactivation after marrow transplantation
7. Recurrent infection with herpes simplex virus after marrow transplantation: Role of the specific immune response and acyclovir treatment
8. Sequential intravenous and twice-daily oral acyclovir for extended prophylaxis of herpes simplex virus infection in marrow transplant patients
9. Prophylactic oral acyclovir after renal transplantation
10. Prevention of herpesvirus infections in renal allograft recipients by low-dose oral acyclovir
11. Prevention of herpes simplex virus infection by oral acyclovir after cardiac transplantation
12. Incidence, distribution, and outcome of episodes of infection in 100 orthotopic liver transplantations
13. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation
14. Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir
15. Herpes simplex virus resistant to acyclovir: A study in a tertiary care center
16. European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
17. Prophylaxis: A strategy to minimise antiviral resistance
18. Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: Preliminary data
19. The prophylactic rote of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation
20. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients
21. Phosphorylation of aciclovir, ganciclovir, penciclovir and S2242 by the cytomegalovirus UL97 protein: A quantitative analysis using recombinant vaccinia viruses
22. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation
23. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation
24. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection
25. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts
26. CMV prophylaxis in high-risk renal transplant patients (D+/R) by acyclovir with or without hyperimmune (CMV) immunoglobulins: A prospective study
27. Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients
28. Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive liver transplant recipients
29. A randomized study of valaciclovir as prophylaxis against CMV infection and disease in BMT recipients
30. Clinical strategies for the management of cytomegalovirus infection and disease in allogeneic bone marrow transplant
31. Acyclovir treatment in infectious mononucleosis: A clinical and virological study
32. Acyclovir treatment in primary Epstein-Barr virus infection: A double- blind placebo-controlled study
33. Effect of acyclovir on infectious mononucleosis: A double-blind, placebo-controlled study
34. Preventing acute rejection, Epstein-Barr virus infection, and post-transplant lymphoproliferative disorders after kidney transplantation: Use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol
35. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy
36. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children
37. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant
38. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: Results of a placebo-controlled, double-blind trial
39. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis
40. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation
41. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; City of Hope-Stanford-Syntex CMV Study Group
42. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation
43. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study
44. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: Risk factors and outcome
45. A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation
46. Arandomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients
47. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients
48. Randomised comparison of ganciclovir and high-dose acyclovir for long- term cytomegalovirus prophylaxis in liver-transplant recipients
49. A double-blind placebo-controlled trial of tow-dose ganciclovir to prevent cytomegalovirus disease after heart transplantation
50. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients
51. A comparison of ganciclovir and aciclovir to prevent cytomegalovirus after lung transplantation
52. A prospective randomized study of aciclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation
53. A controlled trial of ganciclovir to prevent cytomegaloviros disease after heart transplantation
54. Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation
55. High-dose aciclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients: A randomized trial
56. Foscarnet prophylaxis in marrow transplant recipients
57. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in au tologous and allogeneic marrow transplant recipients
58. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections
59. Foscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem celt transplantation (HSCT): A randomized study
60. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): Results of a phase I/II study of a novel antiviral nucleotide analogue
61. Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS
62. Studies of ocular complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS the HPMPC peripheral cytomegalovirus retinitis trial: A randomized, controlled trial
63. Cidofovir for treatment of CMV infection and disease in allogeneic stem celt transplant patients